Evidence map›Paper›PMID 33860036›Full record

ArticleBioMed research international2021

Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro.

Menghuan Guo, Zhiyuan Liu, Jing Si, Jinhua Zhang, Jin Zhao, Zhong Guo, Yi Xie, Hong Zhang, Lu Gan

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Menghuan GuoSchool of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, China.ORCID https://orcid.org/0000-0003-3554-4406
Zhiyuan LiuGansu Key Laboratory of Environmental Friendly Composites and Biomass Utilization, College of Chemical Engineering, Northwest Minzu University, Lanzhou, Gansu 730030, China.ORCID https://orcid.org/0000-0003-1473-9802
Jing SiAdvanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 516029, China.ORCID https://orcid.org/0000-0001-5558-7118
Jinhua ZhangAdvanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 516029, China.ORCID https://orcid.org/0000-0003-2759-1210
Jin ZhaoMedical College of Northwest Minzu University, Lanzhou, Gansu 730030, China.ORCID https://orcid.org/0000-0002-8341-5820
Zhong GuoMedical College of Northwest Minzu University, Lanzhou, Gansu 730030, China.ORCID https://orcid.org/0000-0002-0850-8306
Yi XieAdvanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 516029, China.ORCID https://orcid.org/0000-0002-1790-6314
Hong ZhangAdvanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 516029, China.ORCID https://orcid.org/0000-0002-6039-0640
Lu GanAdvanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong 516029, China.ORCID https://orcid.org/0000-0003-4641-9336
Chinese Academy of Sciences · CNMinzu University of China · CNJi Hua Laboratory · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer death worldwide. Late diagnosis, chemoresistance, and metastasis are the main reasons for the high mortality rate of lung cancer. Therefore, the development of other treatments is urgent. Cediranib (CED), a vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, shows promising antitumour activities in various cancers including lung cancer. Here, we explored the effects and the underlying molecular mechanism of CED on non-small-cell lung cancer (NSCLC) cell line A549 cells in vitro. Our results show that CED could inhibit A549 cell proliferation and cloning formation. Meanwhile, G1 phase cell cycle arrest was also found, as featured by the increased proportion of G1 phase cells as well as the reduction of G1 phase relative proteins CDK4/cyclin D1 and CDK2/cyclin E. Moreover, the ratio of LC3-II/LC3-I was elevated significantly in CED-treated groups compared with the controls. Furthermore, the expression of p-Akt, p-P38, p-Erk1/2, and p-mTOR proteins was decreased obviously in the treatment groups. These results suggest that CED could induce apoptosis and G1 phase cell cycle arrest in A549 cells. Meanwhile, CED may induce autophagy through MAPK/Erk1/2 and Akt/mTOR signal pathway in A549 cells.

Indexed as

A549 CellsApoptosisAutophagyCarcinoma, Non-Small-Cell LungCell ProliferationCell SurvivalG1 Phase Cell Cycle CheckpointsHumansIndolesLung NeoplasmsMAP Kinase Signaling SystemProto-Oncogene Proteins c-aktQuinazolinesReceptors, Vascular Endothelial Growth FactorTOR Serine-Threonine KinasesTumor Stem Cell AssaycediranibIndolesProto-Oncogene Proteins c-aktQuinazolinesReceptors, Vascular Endothelial Growth FactorTOR Serine-Threonine Kinases

Identifiers

PMID33860036
PMCPMC8024085
OpenAlexW3140268976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.